ProfileGDS5678 / 1426738_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 88% 84% 88% 86% 86% 87% 87% 87% 86% 88% 87% 86% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.5676787
GSM967853U87-EV human glioblastoma xenograft - Control 26.881488
GSM967854U87-EV human glioblastoma xenograft - Control 36.2144684
GSM967855U87-EV human glioblastoma xenograft - Control 47.082588
GSM967856U87-EV human glioblastoma xenograft - Control 56.6115286
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.3417986
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.5324787
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.6301687
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.6080587
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.6381486
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.7816388
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.6718887
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.5754386
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.7551188